• Login or create an account
Past events
Watch an event replay
Life Sciences Outlook
Healthcare policy ahead of the US presidential election
This event covers the following:
Country / Territory Risk
Life Sciences
Sourcing and Supply Chain

Following the executive order on 13 September to lower drug prices in the United States, the battleground over US healthcare is taking shape and could fundamentally impact the outlook of the global pharmaceutical industry—all while the coronavirus disease 2019 (COVID-19) pandemic continues to dominate the political agenda.


Gustav Ando
Vice President, Industry Services & Life Sciences, IHS Markit

Margaret Labban, Ph.D.
Life Sciences Senior Analyst, IHS Markit

Milena Izmirlieva
Director, Life Sciences Research, IHS Markit

Timothy Dall
Managing Director - Consulting, Life Sciences, Economics and Country Risk, IHS Markit

Cameron Lockwood
Consulting Associate Director, Life Sciences, IHS Markit

Listen to the roundtable session with the IHS Markit life sciences team, where key discussion points will cover:

  • The introduction of a 'most favored nation' policy on drug pricing in the US—how real and how deep are the risks to the pharmaceutical sector?
  • Healthcare policy ahead of the presidential election
  • Impact of COVID-19 on hospitals and healthcare sector
01 Oct 2020
11:12pm - 11:12pm
IHS Markit Webinar